Genetic Technologies
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 23 Mar 2021
- Reported shorts
- 355K
- Shares on issue
- 9.017B
Genetic Technologies (GTG) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0M (source: ASX (Markit))vs $0 (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$428.6KM (source: ASX (Markit))vs −$1.5M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (basic)
- n/avs −$0.005 (FY25)
- Rev YoY
- n/aFY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of FY26 Annual Report, 14 Sep 2026
Genetic Technologies reported a net loss after tax of $428,603 for FY2026, a 71% improvement from the $1,463,310 loss in FY2025, with revenue falling to just $257 from $4.9 million after selling all operating businesses. No dividend was declared. The company remains suspended from trading on ASX, has net liabilities of $418,603, and its viability depends on securing funding and completing a proposed acquisition of CST Diagnostics to re-comply with listing rules.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0M (source: ASX (Markit)) | $0 | $0 | $8.7MM (source: ASX (Markit)) |
| Gross profit | n/a | −$203.7K | $0 | n/a |
| Operating income | n/a | −$2.8M | −$5.6M | n/a |
| EBITDA | n/a | −$314.5K | −$5.7M | n/a |
| EBIT | n/a | −$392.5K | −$6.1M | n/a |
| Interest expense | n/a | $37.2K | $49.4K | n/a |
| Pretax income | n/a | −$429.7K | −$6.2M | n/a |
| Tax | n/a | $0 | $0 | n/a |
| NPAT | −$428.6KM (source: ASX (Markit)) | −$1.5M | −$12.0M | −$11.8MM (source: ASX (Markit)) |
| Net interest income | n/a | −$17.6K | $70.1K | n/a |
| EPS basic | n/a | −$0.005 | −$0.091 | −$0.012 |
| EPS diluted | n/a | −$0.005 | −$0.091 | −$0.012 |
| Shares | n/a | n/a | 132.2M | 115.4M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- FY26 Annual ReportAnnual Report14 Sep 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report Dec 2025Quarterly Report14 Sep 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report March 2026Quarterly Report14 Sep 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report June 2026Quarterly Report14 Sep 2026via asx_announcements
- Half Yearly Report and Accounts December 2025Half Year Results14 Sep 2026via asx_announcements
- FY25 Appendix 4E & Annual ReportAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report Sept 2025Quarterly Report30 Mar 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report June 2025Quarterly Report30 Mar 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report March 2025Quarterly Report30 Mar 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report20 Aug 2025via asx_announcements
Showing 10 of 95 reports